Humacyte, Inc. ( HUMA) Stock. Should you Buy or Sell? $ 4.51
-0.14 (-3.20 %)
Humacyte, Inc. AnalysisUpdated on 10-09-2022
|Volume Avg.||$428.83 thousand|
|Market Cap||$464.56 M|
|52 Week Range||$3.07 - $16.95|
Humacyte, Inc. opened the day at $4.51 which is -3.20 % on yesterday's close. Humacyte, Inc. has a 52 week high of $16.95 and 52 week low of $3.07, which is a difference of $13.88. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $464.56 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Humacyte, Inc. for $464.56 M, it would take 15 years to get your money back. Humacyte, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Humacyte, Inc. Stock Forecast - Is Humacyte, Inc. a Buy or Sell?
|DCF Score||Strong Buy|
|PB Score||Strong Buy|
|Overall Recommendation||Strong Buy|
Growth and Value
|Net Profit Margin||0.000|
Valuing Humacyte, Inc.
|Price Book Value Ratio||3.266||Price To Book Ratio||3.266|
|Price To Sales Ratio||0.000||Price Earnings Ratio||87.569|
How liquid is Humacyte, Inc.
|Debt Ratio||0.423||Debt Equity Ratio||0.732|
|Long Term Debt To Capitalization||0.127||Total Debt To Capitalization||0.138|
Latest news about Humacyte, Inc.
Humacyte, Inc. (NASDAQ:HUMA ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Lauren Marek - LifeSci Advisors, IR Dr. Laura Niklason - President and CEO Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Dr. Heather Prichard - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer Josh Jennings - Cowen Bruce Jackson - The Benchmark Company Operator Good morning, ladies and gentlemen. And welcome to the Humacyte Second Quarter 2022 Results Conference Call.
DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the second quarter ended June 30, 2022, on Friday, August 12, 2022. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Dale Sander, Chief Financial Officer, and Heather Prichard, Ph.D., Chief Operating Officer, will deliver a corporate presentation in-person at the H.C. Wainwright Global Investment Conference taking place both virtually and in-person at the Fontainebleau Hotel in Miami, on May 24, 2022, at 10:30 a.m. ET.
Humacyte, Inc. (NASDAQ:HUMA ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Lauren Marek - Investor Relations Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Heather Prichard - Chief Operating Officer Conference Call Participants Ryan Zimmerman - BTIG Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Bruce Jackson - The Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Humacyte First Quarter 2022 Results Conference Call. Currently, all participants are in a listen-only mode.
DURHAM, N.C., April 04, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that its 2022 annual meeting of shareholders will be held virtually on Thursday, June 9, 2022, at 7:30 AM eastern time.
About Humacyte, Inc.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.